

Table S1. HER2 Immunohistochemistry Results in Diverse Cancers

| Malignancy Type (N) | HER2 Expression Level | | | | |
|-------------------------------|-----------------------|-------------|-------------|-------------|----------------------------|
| | 0 N (%) | 1+ N (%) | 2+ N (%) | 3+ N (%) | Inadequate Tissue N (%) |
| Adenoid cystic carcinoma (3*) | 33.3 | 0.0 | 66.7 | 0.0 | 0.0 |
| Adrenocortical (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Ampullary (4) | 50.0 | 0.0 | 50.0 | 0.0 | 0.0 |
| Anal (1) | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| Anaplastic Thymoma (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Bladder (7) | 57.1 | 0.0 | 14.3 | 28.6 | 0.0 |
| Cervical (12) | 41.7 | 16.7 | 25.0 | 16.7 | 0.0 |
| Cholangiocarcinoma (27) | 40.7 | 25.9 | 11.1 | 14.8 | 7.4 |
| Chordoma (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Clear Cell Mandible (1) | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| Colorectal (67) | 50.7 | 11.9 | 29.9 | 6.0 | 1.5 |
| Endometrial (9) | 44.4 | 0.0 | 11.1 | 33.3 | 11.1 |
| Gallbladder (5) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Germ Cell Tumour (2) | 50.0 | 0.0 | 0.0 | 50.0 | 0.0 |
| Glioblastoma (2) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hypopharynx (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hepatocellular (4) | 50.0 | 25.0 | 0.0 | 25.0 | 0.0 |
| Leiomyosarcoma (2) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Lung (non-small cell) (34) | 38.2 | 5.9 | 38.2 | 8.8 | 8.8 |
| Lung (small cell) (4) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Melanoma (2) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |

| | | | | | |
|-----------------------------------|-------|------|-------|------|------|
| Meningioma (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Mesothelioma (10) | 80.0 | 0.0 | 10.0 | 0.0 | 10.0 |
| Nasopharyngeal (2) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Neuroendocrine (2) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Oral Cavity (3) | 66.7 | 0.0 | 33.3 | 0.0 | 0.0 |
| Oropharyngeal (1) | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 |
| Ovarian (27) | 40.7 | 18.5 | 33.3 | 7.4 | 0.0 |
| Pancreas (adenocarcinoma) (208) | 26.4 | 11.1 | 48.1 | 11.5 | 2.9 |
| Pancreas (other histology) (11) | 45.5 | 0.0 | 36.4 | 18.2 | 0.0 |
| | | | | | |
| Penile (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Primary peritoneal (mucinous) (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pituitary carcinoma (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Prostate (9) | 55.6 | 22.2 | 22.2 | 0.0 | 0.0 |
| Renal (4 [#]) | 75.0 | 25.0 | 0.0 | 0.0 | 0.0 |
| Sarcoma (5) | 80.0 | 0.0 | 0.0 | 0.0 | 20.0 |
| Salivary Gland (3 ^{\$}) | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 |
| Small Bowel (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Solitary fibrous tumor (2) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Thyroid (8) | 62.5 | 12.5 | 25.0 | 0.0 | 0.0 |
| Unknown Primary (2) | 0.0 | 50.0 | 0.0 | 50.0 | 0.0 |
| Vulva (1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Urothelial (6) | 50.0 | 16.7 | 16.7 | 16.7 | 0.0 |

N: number of cases; %: Percentage of cases; HER2: human epidermal growth factor receptor 2. * primary in trachea, hard palate and larynx (one each); #clear cell (n-2), chromophobe (n-1) and unclassified (n-1); \$polymorphous adenocarcinoma (n-1), acinic cell carcinoma (n-1) and undifferentiated carcinoma of parotid (n-1)